Microbiology FDA 483 (Zydus Lifesciences): Procedures to prevent microbiological contamination did not include adequate validation of the aseptic process
The airflow visualization study conducted on Line *** Protocol Document CHL-QUA-00315-00, effective June 05, 2021, under dynamic conditions did not